N-Acetyl Semax Amidate: A Research Overview

Introduction

N-Acetyl Semax Amidate (Na-Semax-NH₂) is a synthetic heptapeptide derived from the adrenocorticotropic hormone (ACTH) fragment ACTH(4–10). It shares the core amino acid sequence of Semax — Met-Glu-His-Phe-Pro-Gly-Pro — but carries an N-terminal acetyl group and a C-terminal amide in place of the free carboxyl terminus, giving the full structure Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH₂. The compound is classified within the synthetic melanocortin peptide family and has attracted research interest through its structural relationship to Semax, a peptide with an extensive Russian clinical and preclinical literature spanning several decades [1, 2].

Background

Research into ACTH fragments as pharmacologically active entities began in the mid-twentieth century, when investigators observed that sub-sequences of the 39-amino acid ACTH molecule retained behavioral and neurotrophic properties without mediating the adrenal steroidogenic effects of the full hormone. The fragment ACTH(4–10), consisting of the sequence Met-Glu-His-Phe-Pro-Gly-Pro, was identified as particularly active in animal learning models. This fragment formed the scaffold for Semax, developed in the 1980s under the direction of Nikolai F. Myasoedov and Igor P. Ashmarin at the Institute of Molecular Genetics of the Russian Academy of Sciences and Moscow State University [1].

N-Acetyl Semax Amidate represents a further structural modification of Semax, incorporating dual terminal protection — N-terminal acetylation and C-terminal amidation — to investigate whether enhanced metabolic stability alters the pharmacological profile of the parent compound. The terminal-modification strategy builds on the broader ACTH-fragment research tradition; characterizing how each structural variant engages the melanocortin system remains an active area of inquiry [2].

Chemistry and Structure

The core peptide sequence of N-Acetyl Semax Amidate, Met-Glu-His-Phe-Pro-Gly-Pro, is identical to that of Semax. What distinguishes the compound are its terminal modifications:

• N-terminal acetylation: The free alpha-amino group of methionine is replaced by an acetyl group (CH₃CO–). Magrì and colleagues (2016) characterized the effect of N-terminal acetylation on the copper(II) and zinc(II) coordination chemistry of Semax in detail, demonstrating that the chromophore geometry at the copper center shifts from the CuN4 arrangement observed with free Semax to a distorted CuN3O arrangement with N-acetyl Semax, altering the peptide's metal-chelation behavior at physiological pH [2].

• C-terminal amidation: The carboxyl group at the C-terminus of proline is replaced by a primary amide (–NH₂). C-terminal amidation is a naturally occurring post-translational modification found in many endogenous neuropeptides and is associated with resistance to carboxypeptidase-mediated cleavage [3].

Together, these modifications are expected to reduce susceptibility to aminopeptidase attack at the N-terminus and carboxypeptidase attack at the C-terminus, extending the peptide's stability relative to unmodified Semax. Shevchenko and colleagues (2006) demonstrated that intact Semax undergoes rapid enzymatic degradation following intranasal administration in rats, with the tripeptide Pro-Gly-Pro accumulating as a primary metabolite; the terminal-protected variants are understood to resist some of these initial cleavage events [3].

The molecular weight of N-Acetyl Semax Amidate is approximately 870 daltons, consistent with the mass of the Semax heptapeptide backbone plus the acetyl and amide modifications.

Pharmacological Classification

N-Acetyl Semax Amidate is classified as a synthetic melanocortin peptide analog. The melanocortin receptor family — comprising five G-protein-coupled receptor subtypes (MC1R through MC5R) — responds to peptide ligands derived from the proopiomelanocortin (POMC) precursor, which encompasses ACTH, alpha-MSH, and related fragments. ACTH(4–10) itself is considered a minimal pharmacophore within this system, retaining receptor-binding capacity while lacking endocrine potency [1]. Other Russian neuropeptides developed from related research traditions, such as N-Acetyl Selank Amidate, represent parallel lines of inquiry within the same synthetic neuropeptide pharmacology framework.

Levitskaya and colleagues (2005) examined the relationship between N-terminal structure and pharmacological activity across a series of Semax analogs in rat learning models, reporting that the amino acid residue at position 1 of the heptapeptide — methionine in native Semax — was critical for retention of nootropic-like activity. Substitution or loss of methionine reduced or abolished the observed behavioral effects, while certain acyl modifications of the methionine alpha-amino group — including N-terminal acetylation — were reported to retain or modify activity relative to the parent peptide in the tested models [4].

N-Acetyl Semax Amidate does not engage the ACTH steroidogenic pathway at therapeutic research concentrations; the minimal ACTH sequence required for corticosteroid-stimulating activity comprises residues 1–24, well outside the 4–10 fragment represented here [1].

Regulatory Status

N-Acetyl Semax Amidate is sold in the United States as a research-use-only material and is not authorized for human use or approved for any clinical indication in the United States or the European Union.

The parent compound Semax (without N-acetyl or amidate modifications) received regulatory approval from the Russian Ministry of Health for select cerebrovascular indications and has been dispensed in Russian clinical settings for several decades, representing one of the few ACTH-fragment analogs to achieve national regulatory registration. That status pertains to Russia and to the unmodified formulation; it does not extend to N-Acetyl Semax Amidate or confer equivalence under US or EU regulatory frameworks.

Semax (free base and acetate forms) was listed in the FDA's Category 2 bulk drug substances under Section 503A of the Federal Food, Drug, and Cosmetic Act and was scheduled for review by the Pharmacy Compounding Advisory Committee (PCAC) at a meeting on July 24, 2026, to assess potential inclusion on the 503A Bulk Drug Substances List. The N-acetyl amidate variant is not separately named in that proceeding [5]. Research-grade N-Acetyl Semax Amidate from SpartaLabs is verified by independent third-party HPLC and mass spectrometry analysis prior to each batch release.

Discovery History

The scientific lineage of N-Acetyl Semax Amidate traces through the Semax research program initiated in the early 1980s at Moscow's Institute of Molecular Genetics under Myasoedov and Ashmarin. That program systematically investigated ACTH(4–10) analogs, leading to the identification and development of Semax itself. The compound received Russian regulatory approval in the 1990s. Subsequent synthetic chemistry and pharmacology work explored structural modifications — including N-terminal and C-terminal alterations — to characterize the structural determinants of biological activity and metabolic stability [1, 4].

The introduction of dual terminal protection, combining N-acetylation with C-terminal amidation, represents a logical extension of this structure-activity research program. The compound's published history includes the 2016 Magrì study on copper and zinc coordination, which specifically synthesized N-acetyl Semax to characterize the effect of the modification on metal-chelation behavior — work that advanced understanding of how the acetylated terminus changes the peptide's interaction with biologically relevant metals [2]. Structural pharmacology investigation of this compound class continues into the 2020s.

References

1. Koroleva SV, Myasoedov NF. Semax as a universal drug for therapy and research. Biol Bull. 2018;45(6):589–600. DOI: 10.1134/S1062359018060055

2. Magrì A, Munzone A, Peana M, Medici S, Zoroddu MA, Hansson Ö, et al. Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties. J Inorg Biochem. 2016;164:59–69. PMID: 27586814. DOI: 10.1016/j.jinorgbio.2016.08.013

3. Shevchenko KV, Nagaev IY, Alfeeva LY, Andreeva LA, Kamenskii AA, Levitskaia NG, et al. Kinetics of Semax penetration into the brain and blood of rats after its intranasal administration. Russ J Bioorg Chem. 2006;32(1):57–62. DOI: 10.1134/S1068162006010055

4. Levitskaya NG, Sebentsova EA, Andreeva LA, Alfeeva LY, Kamenskiy AA, Myasoedov NF. Effect of modification of the N-terminal region of Semax on the expression of nootropic effect of Semax analogs. Biol Bull. 2005;32(4):381–386. DOI: 10.1007/s10525-005-0116-0

5. US Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Advisory committee calendar. Available at: https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026